OSCO serves as the hub for oncology-related news and advances in Oklahoma. Our organization is made up of clinics and healthcare professionals working together to safeguard the rights of patients and to maintain high medical and ethical standards in the industry.
Pharmacyclics LLC, invites you to attend a Multidisciplinary Discussion during the 2022 ASH Annual Meeting on Incorporating Imbruvica® (ibrutinib) into treatment strategies. The program will be held on Monday December 12th from 8:00 to 9:00 AM in Exhibit Hall/Theater 7 during the ASH Annual Meeting. Session sponsored by Pharmacyclics LLC, an AbbVie company and […]
Read More...AstraZeneca recently announced that the US Food and Drug Administration (FDA) has approved a new indication for IMFINZI® (durvalumab1,2 ), in combination with IMJUDO® (tremelimumab-actl), for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). 1,2 This approval is based on results from the HIMALAYA trial, a Phase III, global, randomized, open-label, multicenter study […]
Read More...The US Food and Drug Administration (FDA) has approved a new indication for IMFINZI® (durvalumab), in combination with gemcitabine and cisplatin, for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).1 BTCs comprise a heterogeneous group of rare cancers, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer, that account for […]
Read More...Join the Oklahoma Society of Clinical Oncology, Inc. for our fall meeting on November 12, 2022, ASCO Direct™, an officially licensed program of the American Society of Clinical Oncology®. This meeting will break down the most clinically relevant abstracts from ASCO’s annual symposium, allowing attendees to engage with the latest strategies in oncology education. Details of the in-person meeting are:
Your company can sponsor OSCO and the work we do by becoming a corporate member today! For more information or to sign up, contact Kathy Musson, OSCO Executive Director at kmussonokc@gmail.com or by phone at 405-850-8334.
The Oklahoma Society of Clinical Oncology (OSCO) is Oklahoma’s only professional organization that represents all those in oncology. Our membership works to advance the sciences of hematology and oncology and its sub-specialties, and to improve services to the public by studying the socio-economic aspects of the practice of our members.
